SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001072613-24-000265
Filing Date
2024-02-22
Accepted
2024-02-22 21:31:04
Documents
1
Group Members
ARCH VENTURE FUND X OVERAGE, L.P.ARCH VENTURE FUND X, L.P.ARCH VENTURE PARTNERS X OVERAGE, L.P.ARCH VENTURE PARTNERS X, L.P.ARCH VENTURE PARTNERS X, LLCARCH VENTURE PARTNERS XII, L.P.ARCH VENTURE PARTNERS XII, LLCKEITH CRANDELLKRISTINA BUROWROBERT NELSENS

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND XII, L.P. - PRIME MEDICINE -- SCH 13D arch-sch13d_18800.htm SC 13D 446620
  Complete submission text file 0001072613-24-000265.txt   448606
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Subject) CIK: 0001894562 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-93800 | Film No.: 24667079
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund XII, L.P. (Filed by) CIK: 0001906837 (see all company filings)

IRS No.: 873448430 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D